D4 dopamine receptor enhances angiotensin II-stimulated aldosterone secretion through PKC-epsilon and calcium signaling.
Aldosterone secretion is subjected to dopaminergic regulation. Our previous study showed that both human D2 and D4 dopamine receptors (D2R and D4R) modulate aldosterone secretion, but in opposing directions. The inhibitory effect of D2R is mediated by attenuating protein kinase C-micro (PKC-micro) and calcium-dependent signaling. The mechanism of D4R effect on angiotensin II (AII)-stimulated aldosterone secretion is explored in this study. Experiments were done with primary human adrenal cortical cells and human adrenocarcinoma (NCI-H295R) cells. Activation of different PKC isoforms was detected by specific phospho-PKC antibodies and PKC translocation. The role of calcium-dependent signaling was examined by measuring the cytoplasmic inositol 1,4,5-triphosphate (IP(3)) and calcium ([Ca(2+)](i)). The D4R agonist PD-168,077 enhanced AII-stimulated aldosterone synthesis and secretion as early as 30 min following exposure independently of the modulation of aldosterone synthase (CYP11B2) transcription. CYP11B2 mRNA level elevated by AII was augmented by D4R in the later period. These effects were reversed by the D4R antagonist L-745,870. AII activated PKC-alpha/betaII, -epsilon, and -micro but not PKC-delta, -theta, or -zeta/lambda of H295R cells. The D4R agonist selectively enhanced AII-stimulated PKC-epsilon phosphorylation and its translocation to the cell membrane. Furthermore, the D4R agonist enhanced the AII-stimulated elevation of intracellular IP(3) and [Ca(2+)](i). Inhibition of PKC-epsilon translocation by the PKC-epsilon-specific inhibitory peptide attenuated AII-stimulated aldosterone secretion, CYP11B2 mRNA expression, and elevation of intracellular IP(3) and [Ca(2+)](i). We conclude that D4R augmented aldosterone synthesis/secretion induced by AII. The mechanisms responsible for this augmentation are mediated through enhancing PKC-epsilon phosphorylation and [Ca(2+)](i) elevation.
Chang
Hong-Wei
HW
Nephrology Division, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Wu
Vin-Cent
VC
Huang
Chao-Yuan
CY
Huang
Hong-Yu
HY
Chen
Yung-Ming
YM
Chu
Tzong-Shinn
TS
Wu
Kwan-Dun
KD
Hsieh
Bor-Shen
BS
D000302:Adrenal Cortex / Q000737:chemistry / Q000187:drug effects / Q000502:physiology; D000306:Adrenal Cortex Neoplasms; D000450:Aldosterone / Q000378:metabolism*; D000804:Angiotensin II / Q000494:pharmacology*; D002118:Calcium / Q000502:physiology*; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D019405:Cytochrome P-450 CYP11B2 / Q000235:genetics; D006801:Humans; D015544:Inositol 1,4,5-Trisphosphate / Q000032:analysis; D010766:Phosphorylation; D051744:Protein Kinase C-epsilon / Q000502:physiology*; D012333:RNA, Messenger / Q000032:analysis; D050638:Receptors, Dopamine D4 / Q000235:genetics / Q000502:physiology*; D015398:Signal Transduction / Q000502:physiology*
D012333:RNA, Messenger; D000804:Angiotensin II; D050638:Receptors, Dopamine D4; D000450:Aldosterone; D015544:Inositol 1,4,5-Trisphosphate; D019405:Cytochrome P-450 CYP11B2; D051744:Protein Kinase C-epsilon; D002118:Calcium